Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Eyal Attar Biography and Net Worth

SVP of Aprea Therapeutics

Eyal C. Attar, M.D. has served as our Senior Vice President, Chief Medical Officer since April 2019. Dr. Attar joined Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of IDHIFA and TIBSOVO for patients with relapsed/refractory AML. Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital and held fellowships in hematology and oncology in the Dana-Farber Partners Cancer Care Hematology/Oncology Fellowship Program. Dr. Attar received his medical degree from the University of North Carolina School of Medicine.

How do I contact Eyal C. Attar?: The corporate mailing address for Dr. Attar and other Aprea Therapeutics executives is 535 BOYLSTON STREET, BOSTON MA, 02116. Aprea Therapeutics can also be reached via phone at 617-463-9385 and via email at [email protected]. Learn More on Eyal C. Attar's contact information.
Has Eyal C. Attar been buying or selling shares of Aprea Therapeutics?: Eyal C. Attar has not been actively trading shares of Aprea Therapeutics in the last ninety days. Most recently, Eyal C. Attar sold 1,800 shares of the business's stock in a transaction on Monday, February 28th. The shares were sold at an average price of $34.60, for a transaction totalling $62,280.00. Learn More on Eyal C. Attar's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 4 times. They purchased a total of 13,938 shares worth more than $86,719.14. The most recent insider tranaction occured on March, 13th when CFO John P Hamill bought 1,010 shares worth more than $7,362.90. Insiders at Aprea Therapeutics own 20.9% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 3/13/2024.

Eyal C. Attar Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/28/2022	Sell	1,800	$34.60	$62,280.00
9/16/2021	Sell	798	$93.60	$74,692.80

Eyal C. Attar Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $5.73

$5.71

$5.85

50 Day Range

MA: $6.50

$5.43

$8.46

2 Week Range

Now: $5.73

$2.78

$8.85

Volume

2,294 shs

Average Volume

11,404 shs

Market Capitalization

$31.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad